Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 3, Pages 294-306
Publisher
Springer Nature
Online
2013-10-09
DOI
10.1038/clpt.2013.208
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells
- (2013) D. K. Hiwase et al. HAEMATOLOGICA
- Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
- (2012) Ophelia Q. P. Yin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells
- (2012) D L White et al. LEUKEMIA
- Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
- (2012) Laura N. Eadie et al. LEUKEMIA & LYMPHOMA
- Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1
- (2011) Marta Gromicho et al. LEUKEMIA & LYMPHOMA
- Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways
- (2011) Carine Tang et al. LEUKEMIA & LYMPHOMA
- The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes
- (2010) Manuela Dezi et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib
- (2010) Erin R. Gardner et al. CANCER BIOLOGY & THERAPY
- Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
- (2010) Deborah L. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
- (2009) Amit K. Tiwari et al. BIOCHEMICAL PHARMACOLOGY
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- ABC Efflux Pump-Based Resistance to Chemotherapy Drugs
- (2009) Paul D. W. Eckford et al. CHEMICAL REVIEWS
- Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
- (2009) J. S. Lagas et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
- (2009) C Tanaka et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
- (2009) Y. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
- (2009) D K Hiwase et al. LEUKEMIA
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
- (2009) Elias Jabbour et al. MAYO CLINIC PROCEEDINGS
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia
- (2008) A. Giannoudis et al. BLOOD
- Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
- (2008) Kunihiro Suzuki et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
- (2008) Gergely Szakács et al. DRUG DISCOVERY TODAY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search